Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14093 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 139 of 141 pages ‹ First < 137 138 139 140 141 >
HSL2634
Martin JB, Kasper DL.
In whose best interest? Breaching the academic-industrial wall
New England Journal of Medicine 2000 November 30; 343:(22):1646-1649
http://content.nejm.org/cgi/content/extract/343/22/1646
HSL2577
Weber W.
Merck Sharp & Dohme prosecuted for pampering Dutch doctors
Lancet 2000 Nov 25; 356:1832
HSL19753
Gilbert D, Walley T, New B
Lifestyle medicines
BMJ 2000 Nov 25; 321:1341-1344
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1119073/
HSL3678
Findlay S.
Prescription Drugs and Mass Media Advertising.
Washington, DC: National Institute of Health Care Management. 2000 Nov
http://web.archive.org/web/20080304043214/http://www.nihcm.org/publications/prescription_drugs
HSL1416
Jureidini JN.
Epidemic of schizophrenia in children or inappropriate prescribing?
Med J Aust 2000 Nov 20; 173:(10):555-6
HSL19535
Stolberg SG, Gerth J
High-Tech Stealth Being Used to Sway Doctor Prescriptions
The New York Times 2000 Nov 16
http://www.nytimes.com/2000/11/16/us/high-tech-stealth-being-used-to-sway-doctor-prescriptions.html
HSL19536
Petersen M.
Growing Opposition to Free Drug Samples
The New York Times 2000 Nov 15
http://www.nytimes.com/2000/11/15/business/growing-opposition-to-free-drug-samples-ultimate-costs-and-safety-are-cited.html
HSL2632
McCarthy M.
Company sought to block paper's publication
Lancet 2000 Nov 11; 356:1659
HSL2583
Summers W, Driscoll J, Orient J.
The pharmaceutical industry - to whom is it accountable? (7th of 10 letters)
New England Journal of Medicine 2000 Nov 9; 343:(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL2586
Schwarting J.
The pharmaceutical industry - to whom is it accountable? (3rd of 10 letters)
New England Journal of Medicine 2000 Nov 9; 343:(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL2587
Schwarting JS.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9; 343:(19):1416
HSL2594
Rightor N.
The pharmaceutical industry - to whom is it accountable? (6th of 10 letters)
New England Journal of Medicine 2000 Nov 9; 343:(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL2602
Reif M.
The pharmaceutical industry - to whom is it accountable? (2nd of 10 letters)
New England Journal of Medicine 2000 Nov 9; 343:(19):1415-6
http://content.nejm.org/cgi/content/full/343/19/1415
HSL2629
Mehta DJ.
The pharmaceutical industry - to whom is it accountable? (9th of 10 letters)
New England Journal of Medicine 2000 Nov 9; 343:(19):1417
HSL6968
Bohrer RA.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9; 343:(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL6969
Hayes TA.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9; 343:(19):1416
http://content.nejm.org/cgi/content/full/343/19/1415
HSL6970
Holmer AF.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9; 343:(19):1415
http://content.nejm.org/cgi/content/full/343/19/1415
HSL6971
Jacobs C.
The pharmaceutical industry--to whom is it accountable?
N Engl J Med 2000 Nov 9; 343:(19):1416-7
http://content.nejm.org/cgi/content/full/343/19/1415
HSL2016
Biotech Firm Tries to Suppress Publication of Research: Academic Freedom at Heart of Issue
Journal of the American Medical Association 2000 Nov 1
HSL18019
Kravitz RL
Direct-to-Consumer Advertising of Prescription Drugs: Implications for the Patient-Physician Relationship
JAMA 2000 Nov 1; 284:(17):2244
http://jama.ama-assn.org/cgi/content/full/284/17/2244
HSL1855
Potdar RD.
Educating ourselves.
Indian Pediatr 2000 Nov; 37:(11):1287-8
http://www.indianpediatrics.net/nov2000/nov-1287-1288.htm
HSL3695
Rowsell LB.
Policy statement. Advertising campaigns of branded and unbranded messages.
: Therapeutic Products Directorate, Health Canada. 2000 Nov
http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/policy/issued/adv_campaign_e.html.
HSL7895
Wechsler J.
FDA launches debate on renewing user fees and updating FDA Modernization Act
Formulary 2000 Nov; 35:925-926
HSL7897
Pines WL.
Direct-to-consumer advertising.
Ann Pharmacother 2000 Nov; 34:(11):1341-4
http://www.theannals.com/cgi/reprint/34/11/1341
HSL16022
Zoutman DE, Ford BD, Bassili AR.
A call for the regulation of prescription data mining
CMAJ 2000 Oct 30; 163:(9):1146
http://www.cmaj.ca/cgi/content/full/163/9/1146
HSL7038
More U.S. Children Being Diagnosed With Youthful Tendency Disorder
The Onion 2000 Oct 27
HSL7816
Tieman J.
Just roiling along.
Mod Healthc 2000 Oct 23; 30:(44):8-9
HSL16740
Wolfe S, Lurie P
Protecting Patients in Medical Research
The Washington Post 2000 Oct 17
HSL19537
Page L
More Clinics Ban Drug Samples, Citing Cost, Safety Concerns
American Medical News 2000 Oct 16
http://www.ama-assn.org/amednews/2000/10/16/bil11016.htm
HSL6967
Kiln MR, Hirst JMD.
Academia and industry
Lancet 2000 Oct 14; 356:1359
HSL18018
Reichert S, Simon T, Halm EA.
Physicians' attitudes about prescribing and knowledge of the costs of common medications.
Arch Intern Med 2000 Oct 9; 160:(18):2799-803
http://archinte.ama-assn.org/cgi/content/full/160/18/2799
HSL226
Freemantle N, Anderson IM, Young P.
Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis.
Br J Psychiatry 2000 Oct; 177:292-302
http://bjp.rcpsych.org/cgi/content/full/177/4/292
HSL2099
Norman GR.
The epistemology of clinical reasoning: perspectives from philosophy, psychology, and neuroscience.
Acad Med 2000 Oct; 75:(10):
http://www.academicmedicine.org/cgi/content/full/75/10/S127?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=Norman+G&titleabstract=epistemology&searchid=1124492605605_451&stored_search=&FIRSTINDEX=0&journalcode=acadmed
HSL2582
Susman E.
No such thing as a free lunch
Scrip Magazine 2000 October; 94:(19):
HSL2627
Mintzes B, Lippman A.
Re: Selling, or selling out? [response]
Journal of the Society of Obstetricians and Gynaecologists of Canada 2000 Oct; 22:(10):786-787
HSL4817
Bhatt AD.
Clinical trial publications.
Issues Med Ethics 2000 Oct-Dec; 8:(4):119-21
HSL5690
Kimanani E, Stypinski D, Curtis G, Stiles M, Heessels P, Logan S, Nelson K, St Germain E, Boswell G.
A contract research organization's response to the new FDA guidances for bioequivalence/bioavailability studies for orally administered drug products.
J Clin Pharmacol 2000 Oct; 40:(10):1102-8
HSL6963
Baumgartner A.
Re: Selling, or selling out?
Journal of the Society of Obstetricians and Gynaecologists of Canada 2000 Oct; 22:(10):786
HSL6964
Feldman W.
The pharmaceutical industry/L'industrie pharmaceutique
Annales CRMCC 2000 Oct; 33:(7):404-405
HSL6965
Kravitz RL.
Direct-to-consumer advertising of prescription drugs.
West J Med 2000 Oct; 173:(4):221-2
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=11017964
HSL6966
Davis JJ.
Riskier than we think? The relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs
J Health Commun 2000 Oct; 5:(4):349-69
HSL7823
Challenges and opportunities in the Canadian drug industry
HealthCare Distributors 2000 Oct; 52:18, 20-21
HSL19538
The Fiscal Policy Institute for USAction
Impossible Choices: Food and Housing or Prescription Drugs?
Fiscal Policy Institute 2000 Oct
www.fiscalpolicy.org/downloads/ImpossibleChoices.pdf
HSL19819
Wagner E, Tumas JA, Field EA, Glazer NB, Schulz G, Grossman L
Letter To The Editor: Good Publication Practice Guidelines For Pharmaceutical Companies
CMAJ 2000 Oct; 14:(9):749
HSL228
de Barros JAC.
One more case of the double standard: discrepancies between drug information provided to Brazilian and American physicians
Pharmacoepidemiology and Drug Safety 2000; 9:281-287
http://www3.interscience.wiley.com/cgi-bin/abstract/73501719/ABSTRACT
HSL19541
Pear R
Marketing Tied to Increase in Prescription Drug Sales
The New York Times 2000 Sep 20
http://www.nytimes.com/2000/09/20/us/marketing-tied-to-increase-in-prescription-drug-sales.html?pagewanted=all&src=pm
HSL2584
Sullivan P.
Freebies to MDs targeted as drug industry starts publicizing CME fines
Canadian Medical Association Journal 2000 Sep 19; 163:(6):749
HSL6962
Horton R.
The less acceptable face of bias.
Lancet 2000 Sep 16; 356:(9234):959-60
http://linkinghub.elsevier.com/retrieve/pii/S0140673600027112
HSL6961
Bruera E, Ripamonti C, Beattie-Palmer L.
Use of trade names of drugs in abstracts from pain congresses.
N Engl J Med 2000 Sep 14; 343:(11):818
HSL2015
Borger J.
Dirty rats leave Gore a subliminal message
The Guardian 2000 Sep 13
http://www.guardian.co.uk/world/2000/sep/13/uselections2000.usa
HSL7906
Kirkpatrick MA, Shadis ER.
Pharmacy connect-free drug program for community dwelling elders
Journal of the American Pharmaceutical Association 2000 Sep 10; 40:672-674
HSL2014
Medawar C
Costly benefits and the conspiracy of goodwill
Paper given at the annual meeting of the British Association for the Advancement of Science 2000 Sep 9
HSL19856
Kent A
Not another magic bullet
BMJ 2000 Sep 9; 321:(7261):644
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1118524/
HSL1857
Drug-company influence on medical education in USA
Lancet 2000 Sep 2; 356:(9232):781
http://linkinghub.elsevier.com/retrieve/pii/S0140673600026453
HSL2633
McCarthy M.
Conflict of interest taints vaccine approval process, charges US report.
Lancet 2000 Sep 2; 356:(9232):838
HSL18017
Farrell L
Ads: O Liberty! what crimes are committed in thy name!
BMJ 2000 Sep 2; 321:(7260):578
http://www.bmj.com/cgi/content/citation/321/7260/578
HSL2615
Wenger NS, Lieberman JR.
The orthopaedic surgeon and industry. Ethics and industry incentives.
Clinical Orthopaedics and Related Research 2000 September 01; (378):39-43
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10986972http://
HSL233
Backer EL, Lebsack JA, Van Tonder RJ, Crabtree BF.
The value of pharmaceutical representative visits and medication samples in community-based family practices.
J Fam Pract 2000 Sep; 49:(9):811-6
HSL2589
Sams WM, Freedberg IM.
The dermatology-industry interface: defining the boundaries.
J Am Acad Dermatol 2000 Sep; 43:(3):550-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10954674
HSL3682
Galbally R.
Review of drugs, poisons, and controlled substances legislation. Draft Final Report.
Canberra: Therapeutic Goods Administration, 2000 Sep
HSL6960
Gifts: a transcript of a television report
MaLAM International News 2000 Sep-Oct; 18:(9-10):1-4
HSL7847
Thompson L.
User fees for faster drug reviews: are they helping or hurting the public health?
FDA Consumer 2000 Sep-Oct; 34:25-29
HSL19780
Sara G, Prior N
Drug Companies and CME: Prohibition, Declaration or Engagement?
Australas Psychiatry 2000 Sep; 8:(3):195-198
http://apy.sagepub.com/content/8/3/195.full
HSL3701
Petersen M.
What’s black and white and sells medicine?
NY Times 2000 Aug 2712 [sect 3, p1].
HSL14738
Stock S.
Luxury lures give doctors the drug company habit
The Australian 2000 Aug 26-27
HSL7902
Conlan MF.
Congress takes step to let RPhs import Rx drugs
Drug Topics 2000 Aug 21; 144:61
HSL4609
Williams R.
Pharmaceutical Industry and the media
Radio National 2000 Aug 20
http://www.abc.net.au/rn/science/ockham/stories/s164976.htm
HSL227
Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH.
The uncertainty principle and industry-sponsored research.
Lancet 2000 Aug 19; 356:(9230):635-8
http://linkinghub.elsevier.com/retrieve/pii/S0140673600026052
HSL6959
Editorial .
Experimenting with direct-to-consumer advertising
The Lancet 2000 Aug 19; 356:607
HSL7834
Pharmacists say no to DTC promotions
Chemist and Druggist 2000 Aug 19; 254:
HSL2574
Young S.
Is academic medicine for sale? (3rd of 13 letters)
New England Journal of Medicine 2000 Aug 17; 343:(7):508-509
http://content.nejm.org/cgi/content/full/343/7/508
HSL2591
Ruane T.
Is academic medicine for sale? (10th of 13 letters)
New England Journal of Medicine 2000 Aug 17; 343:(7):510
http://content.nejm.org/cgi/content/full/343/7/508
HSL2593
Ross L.
Is academic medicine for sale? (1st of 13 letters)
New England Journal of Medicine 2000 Aug 17; 343:(7):508
http://content.nejm.org/cgi/content/full/343/7/508
HSL2618
Norton JW.
Is academic medicine for sale? (2nd of 13 letters)
New England Journal of Medicine 2000 Aug 17; 343:(7):508
http://content.nejm.org/cgi/content/full/343/7/508
HSL2619
Newman TJ.
Clinical investigators and the pharmaceutical industry (1st of 3 letters)
New England Journal of Medicine 2000 Aug 17; 343:(7):510-511
http://content.nejm.org/cgi/content/full/343/7/510
HSL2628
Miller P.
Is academic medicine for sale? (12th of 13 letters)
New England Journal of Medicine 2000 Aug 17; 343:(7):510
http://content.nejm.org/cgi/content/full/343/7/508
HSL6950
Bellin E.
Clinical investigators and the pharmaceutical industry.
N Engl J Med 2000 Aug 17; 343:(7):511
http://content.nejm.org/cgi/content/full/343/7/510
HSL6953
Dillon DC.
Is academic medicine for sale? (6th of 13 letters)
New England Journal of Medicine 2000 Aug 17; 343:(7):509
http://content.nejm.org/cgi/content/full/343/7/508
HSL6954
Firlik AD, Lowry DW.
Is academic medicine for sale?
N Engl J Med 2000 Aug 17; 343:(7):509-10
http://content.nejm.org/cgi/content/full/343/7/508
HSL6955
Hagan BM.
Is academic medicine for sale? (11th of 13 letters)
New England Journal of Medicine 2000 Aug 17; 343:(7):510
http://content.nejm.org/cgi/content/full/343/7/508
HSL6956
Jagger J.
Is academic medicine for sale?
N Engl J Med 2000 Aug 17; 343:(7):509
http://content.nejm.org/cgi/content/full/343/7/508
HSL6957
Lebowitz J.
Is academic medicine for sale?
N Engl J Med 2000 Aug 17; 343:(7):509
http://content.nejm.org/cgi/content/full/343/7/508
HSL6958
Leong GB, Silva AJ.
Is academic medicine for sale? (5th of 13 letters)
New England Journal of Medicine 2000 Aug 17; 343:(7):509
http://content.nejm.org/cgi/content/full/343/7/508
HSL6949
McCarthy M.
Medical-education companies come under fire in USA
Lancet 2000 Aug 5; 356:494
HSL7911
Sellers JA.
The two faces of direct-to-consumer advertising.
Am J Health Syst Pharm 2000 Aug 1; 57:(15):1401
http://www.ajhp.org/cgi/reprint/57/15/1401
HSL7914
Thompson CA.
Medicare to use new wholesale drug prices, says Shalala
American Journal of Health System Pharmacy 2000 Aug 1; 57:1384, 1386
HSL18013
Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M, Benser M, Edmondson AC, Bates DW.
Incidence and preventability of adverse drug events in nursing homes.
Am J Med 2000 Aug 1; 109:(2):87-94
http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(00)00451-4
HSL6947
Conflicts of interest (Relations between health professionals and industry)
Prescrire International 2000 Aug; 9:(48):126
HSL6948
Chepesiuk R, Perkin RL.
Who looks at drug advertising?
Canadian Family Physician 2000 Aug; (46):
HSL7839
Carpenter D.
Bitter pills
Hospitals and Health Networks 2000 Aug; 74:48-52
HSL17263
Sleight P
Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!
Current Controlled Trials in Cardiovascular Medicine 2000 July 31; 1:(1):25-27
http://trialsjournal.com/content/1/1/25
HSL19540
Stolberg SG, Gerth J
How Companies Stall Generics and Keep Themselves Healthy
The New York Times 2000 July 23
http://www.commondreams.org/headlines/072300-03.htm
HSL2626
Montauk L.
Medical junk mail.
Lancet 2000 Jul 22; 356:(9226):344
HSL6946
Durrington PN, Chantler K.
Academia and industry.
Lancet 2000 Jul 22; 356:(9226):339
HSL19539
Ross JS, Lurie P, Wolfe SM
Medical Education Services Supplies: A Threat to Physician Education. Public Citizen
Public Citizen 2000 July 19
http://www.citizen.org/hrg1530
HSL2575
Wolfe S, Lurie P, Sasich L, Barbehenn E.
Information on thiazolidinediones (1st of 2 letters)
The Lancet 2000 Jul 15; 356:254-5
HSL6945
Auwerx J.
Information on thiazolidinediones (2nd of 2 letters)
The Lancet 2000 Jul 15; 356:255
HSL16739
Wolfe SM, Lurie P, Sasich LD, Barbehenn E.
Information on thiazolidinediones.
Lancet 2000 Jul 15; 356:(9225):254-5
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)74507-4
HSL2603
Recker RR.
Disclosure of authors' conflicts of interest--a follow-up.
N Engl J Med 2000 Jul 13; 343:(2):146
http://content.nejm.org/cgi/content/full/343/2/146
HSL2617
Recker RR.
Disclosure of authors' conflicts of interest - A follow-up (2nd of 4 letters)
New England Journal of Medicine 2000 Jul 13; 343:(2):146
http://content.nejm.org/cgi/content/full/343/2/146
Page 139 of 141 pages ‹ First < 137 138 139 140 141 >
